P
P. Vestergaard
Researcher at Aarhus University Hospital
Publications - 60
Citations - 4880
P. Vestergaard is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Osteoporosis & Population. The author has an hindex of 30, co-authored 60 publications receiving 4539 citations. Previous affiliations of P. Vestergaard include Aarhus University.
Papers
More filters
Journal ArticleDOI
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk
TL;DR: Type 1 and type 2 diabetes are associated with an increased risk of any fracture and hip fractures, and the use of drugs to control diabetes may reduce the association between diabetes and fractures.
Journal ArticleDOI
High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition
Morten Poulsen,P. Vestergaard,Berthil F. Clasen,Yulia Radko,Lars Porskjær Christensen,Hans Stødkilde-Jørgensen,Niels Møller,Niels Jessen,Steen B. Pedersen,Jens Otto Lunde Jørgensen +9 more
TL;DR: The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.
Journal ArticleDOI
Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis.
T. Hagenau,R. Vest,T. N. Gissel,C. S. Poulsen,Mogens Erlandsen,Leif Mosekilde,P. Vestergaard +6 more
TL;DR: A widespread global vitamin D insufficiency was present compared with proposed threshold levels, and serum 25(OH)D levels were higher in subjects aged aged >15 years than in younger subjects.
Journal ArticleDOI
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.
TL;DR: Proton pump inhibitors appeared to be associated with a limited increase in fracture risk, in contrast to histamine H2 antagonists, which seemed to beassociated with a small decrease in fracturerisk.
Journal ArticleDOI
Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications.
TL;DR: Patients with a hip fracture have a pronounced excess mortality risk and the main cause was linked to the trauma that caused the fracture event and not to pre-existing co-morbidity.